Ignite Creation Date:
2024-05-05 @ 5:00 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00367731
Status:
COMPLETED
Last Update Posted:
2006-08-23
First Post:
2006-08-22
Brief Title:
NOW Thai HAART Study
Sponsor:
Rajavithi Hospital
Organization:
Rajavithi Hospital
Study Overview
Official Title:
Neurological Outcomes With in THAI National HAART Program
Status:
COMPLETED
Status Verified Date:
2006-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
After Initiation of HAART in peoples who living with HIVAIDS in Thailand by the year 2000 rapidly expanded HAART access of national project has been promoted in 2004 Free ARVs For CD4200cellcumm or in symptomatic HIV with CD4250 cellcumm and CD4 monitoring has been available The first-line regimen is d4T3TCNVP in mainly the first time Naive patients CD4 response rate of opportunistic infection and neurological outcomes were measured Rate of ARV change adverse eventstreatment failure TB co-infection rate percent changing to EFV-based regimen or PI-based regimen were recorded
Any Adverse Events including Sever rash Severe Hepatitis Lipid abnormalities Severe Anemia and Other common AEs will be analysed
Any Adverse Events including Sever rash Severe Hepatitis Lipid abnormalities Severe Anemia and Other common AEs will be analysed
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None